title: Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches.
abstract: The role of nitric oxide and its reactive derivatives (NOx) is well known in the pathogenesis of multiple sclerosis, which is an inflammatory disease while NOxseems to be important in coordinating inflammatory response. The purpose of the present study was to assess serum NOxas one of the nitrogen species and inflammatory parameters in relapsing-remitting multiple sclerosis patients and to compare the effectiveness of various types of disease-modifying therapies that reduce nitric oxide and inflammatory biomarkers. Elevated NOxlevel was observed in patients who received the first-line disease-modifying therapy (interferons beta-1a and beta-1b) in comparison with the subjects treated with the second-line disease-modifying therapy (natalizumab; fingolimod) and healthy controls without significant differences in C-reactive protein and interleukin-1 beta. A negative correlation was observed between serum NOxlevel and the duration of multiple sclerosis confirmed in the whole study population and in subjects treated with the first-line agents. Only serum NOx, concentration could reveal a potential efficacy of disease-modifying therapy with a better reduction in NOxlevel due to the second-line agents of disease-modifying therapy.
authors.affiliation: Department of Neurology in Zabrze, Medical University of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
authors.forename: Natalia
authors.identifier: 0000-0003-0834-5727
authors.initials: N
authors.lastname: Niedziela
authors.affiliation: Department of Neurology in Zabrze, Medical University of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Adamczyk-Sowa
authors.affiliation: 3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Silesian Centre for Heart Disease, ul. Curie-Skłodowskiej 9, 41-800 Zabrze, Poland.
authors.forename: Jacek T
authors.initials: JT
authors.lastname: Niedziela
authors.affiliation: Department of Microbiology and Immunology in Zabrze, Medical University of Silesia, ul. Jordana 19, 41-808 Zabrze, Poland.
authors.forename: Bogdan
authors.initials: B
authors.lastname: Mazur
authors.affiliation: Department of Radiology in Zabrze, Medical University of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Kluczewska
authors.affiliation: Department of Laryngology in Zabrze, Medical University of Silesia, ul. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland.
authors.forename: Paweł
authors.initials: P
authors.lastname: Sowa
authors.affiliation: 3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Silesian Centre for Heart Disease, ul. Curie-Skłodowskiej 9, 41-800 Zabrze, Poland.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Gąsior
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D000068556:Interferon beta-1a / Q000008:administration & dosage / Q000378:metabolism; D000068576:Interferon beta-1b / Q000008:administration & dosage / Q000378:metabolism; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D000069442:Natalizumab / Q000008:administration & dosage; D009569:Nitric Oxide / Q000097:blood; D026361:Reactive Nitrogen Species / Q000097:blood*
chemical_list: D015415:Biomarkers; D000069442:Natalizumab; D026361:Reactive Nitrogen Species; D000068576:Interferon beta-1b; D009569:Nitric Oxide; D000068876:Fingolimod Hydrochloride; D000068556:Interferon beta-1a